TB-500 Research for Anti-Fibrosis
An evidence-based overview of research examining TB-500 in the context of anti-fibrosis. This page synthesizes findings from peer-reviewed literature.
Research Summary
Thymosin beta-4 demonstrates anti-fibrotic effects across multiple organ systems in preclinical studies. Italian researchers showed reduced lung fibrosis in bleomycin-induced models (Conte et al., 2013). Chinese studies demonstrated cardiac anti-fibrosis through TGF-b1/Smad3 pathway blockade. Korean research on liver fibrosis showed attenuation of hepatic stellate cell activation, suggesting potential benefits for liver disease. The mechanism appears to involve modulation of inflammatory and fibrotic signaling pathways. These anti-fibrotic effects remain preclinical. No human trials have specifically evaluated TB-500 or thymosin beta-4 for fibrotic conditions.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Anti-Fibrosis
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. TB-500 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.